ArticleCureus2026
Association of Serum Estradiol and Testosterone With Hip Fractures in Elderly Men.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHip fractures in the elderly are a major public health concern due to high morbidity, mortality, and long-term disability. While men have a lower incidence of hip fractures than women, the risk rises sharply with age, and outcomes in men are often worse. Sex steroids (especially estrogen and testosterone) play a crucial role in bone metabolism, but their contribution to osteoporosis and fracture risk in elderly men remains under-investigated, particularly in diverse populations. This prospective case-control study aimed to determine whether serum estradiol and testosterone levels differ significantly between elderly South Indian men with osteoporotic hip fractures and age-matched healthy controls.
methodsA prospective case-control study was conducted on men over 55 years of age at a South Indian tertiary hospital (March-May 2022). Fifty men with osteoporotic hip fractures (cases) and 50 age-matched healthy male controls were recruited. Clinical data (age, body mass index, smoking status) were collected, and serum total estradiol and testosterone levels were measured using enzyme-linked fluorescent immunoassay. Overt androgen deficiency was defined as total testosterone <2 ng/mL, and possible deficiency as 2-4 ng/mL. Group comparisons were performed using independent t-tests or Mann-Whitney tests for continuous variables and Fisher's exact test for categorical variables, with significance set at p<0.05.
resultsThe majority of hip fracture cases were in the 65-75 years age group (25, 50%). Cases had a high prevalence of low sex hormones: 22 (44%) had overt androgen deficiency and 26 (52%) had possible androgen deficiency, compared to only two (4%) of controls with testosterone <2 ng/mL. Mean serum testosterone in cases was significantly lower than in controls (2.40±1.12 vs. 4.22±1.62 ng/mL, p<0.001), and mean estradiol was also lower in cases (32.07±10.08 vs 41.88±17.99 pg/mL, p=0.008). Low estradiol levels were more frequent in cases: only 21 (42%) of cases had high-normal estradiol (≥34.3 pg/mL) vs. 30 (60%) of controls. There were no significant differences in body mass index or smoking status between cases and controls (p>0.05).
conclusionElderly men with hip fractures had significantly lower serum testosterone and estradiol levels than age-matched controls, demonstrating an association between reduced sex hormone levels and hip fracture status. These findings support a possible role of sex hormones in male skeletal health, but causal relationships and therapeutic implications cannot be inferred from this study and require confirmation in larger prospective investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.